Now scientists at the Scripps Research Institute in La Jolla, Calif., report that a kappa-opioid receptor antagonist infused into the central amygdala of cocaine-addicted rats lessened hyperactive and anxiety-like behavior usuaslly seen in withdrawal, wrote Marisa Roberto, Ph.D., and colleagues online June 10 in Biological Psychiatry.
Blocking kappa-opioid and other pathways to the “dark side” of addiction might prove “a viable therapeutic strategy for cocaine addiction” while keeping positive motivational pathways open to the ordinary pleasures of life, they said.
To read more about research at Scripps on the “dark side” of addiction, see Psychiatric News here.
(Image: Sebastian Kauliztki/Shutterstock.com)